Tenax Therapeutics
TENX
18 hedge funds and large institutions have $38.5M invested in Tenax Therapeutics in 2014 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 5 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
13% more funds holding
Funds holding: 16 → 18 (+2)
17% less capital invested
Capital invested by funds: $46.5M → $38.5M (-$8.09M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
90% less call options, than puts
Call options by funds: $361K | Put options by funds: $3.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$4.78M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$3.55M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.93M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$1.54M |
| 5 |
D.E. Shaw & Co
New York
|
+$617K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$8.32M |
| 2 |
DM
Deerfield Management
New York
|
-$2.16M |
| 3 |
Millennium Management
New York
|
-$956K |
| 4 |
Morgan Stanley
New York
|
-$154K |
| 5 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$154K |
TENX Hedge Fund Activity: Q2 2014 in Review
18 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q2 2014, worth a combined $38.5M — down 17% from $46.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TENX positions and 5 closed out — a net gain of 2 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $4.78M. The largest seller was HealthCor Management, exiting entirely with an estimated $8.32M sold.
- 18 institutional investors held Tenax Therapeutics (TENX) as of Q2 2014, up from 16 in Q1 2014.
- Funds reported $38.5M of Tenax Therapeutics stock for Q2 2014, down 17% quarter-over-quarter.
- 7 funds opened new Tenax Therapeutics positions in Q2 2014 and 5 closed out, a net change of +2 holders.
- The largest Tenax Therapeutics buyer in Q2 2014 was Broadfin Capital, an estimated $4.78M added.
- The largest Tenax Therapeutics seller in Q2 2014 was HealthCor Management, an estimated $8.32M sold.
Based on aggregated 13F filings for Q2 2014.